Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 10/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044614 | 1.00 | ALOX5AP (0.48) | ALOX5APRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL6044456 | 1.00 | ALOX5AP (0.48) | ALOX5APRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL4642584 | 0.79 | ALOX5AP (0.55) | ALOX5APRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL6949100 | 0.78 | ALOX5AP (0.48) | ALOX5APRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL6940748 | 0.78 | ALOX5AP (0.48) | ALOX5APRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL6044140 | 0.78 | REN (0.48) | RENSLC2A1BCHE | |
| SCHEMBL6045096 | 0.78 | REN (0.48) | RENSLC2A1BCHE | |
| SCHEMBL6044629 | 0.77 | CYP4F2 (0.57) | BCHE | |
| SCHEMBL6044633 | 0.77 | CYP4F2 (0.57) | BCHE | |
| SCHEMBL22027685 | 0.76 | MMP1 (0.58) | MMP1CYP3A4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | ALOX5AP 449/4885RXRA 102/4885RXRB 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.